A role for cyclin-dependent kinase(s) in the modulation of fast anterograde axonal transport: effects defined by olomoucine and the APC tumor suppressor protein.
Proteins that interact with both cytoskeletal and membrane components are candidates to modulate membrane trafficking. The tumor suppressor proteins neurofibromin (NF1) and adenomatous polyposis coli (APC) both bind to microtubules and interact with membrane-associated proteins. The effects of recombinant NF1 and APC fragments on vesicle motility were evaluated by measuring fast axonal transport along microtubules in axoplasm from squid giant axons. APC4 (amino acids 1034-2844) reduced only anterograde movements, whereas APC2 (aa 1034-2130) or APC3 (aa 2130-2844) reduced both anterograde and retrograde transport. NF1 had no effect on organelle movement in either direction. Because APC contains multiple cyclin-dependent kinase (CDK) consensus phosphorylation motifs, the kinase inhibitor olomoucine was examined. At concentrations in which olomoucine is specific for cyclin-dependent kinases (5 microM), it reduced only anterograde transport, whereas anterograde and retrograde movement were both affected at concentrations at which other kinases are inhibited as well (50 microM). Both anterograde and retrograde transport also were inhibited by histone H1 and KSPXK peptides, substrates for proline-directed kinases, including CDKs. Our data suggest that CDK-like axonal kinases modulate fast anterograde transport and that other axonal kinases may be involved in modulating retrograde transport. The specific effect of APC4 on anterograde transport suggests a model in which the binding of APC to microtubules may limit the activity of axonal CDK kinase or kinases in restricted domains, thereby affecting organelle transport.
Ratner
N
N
Department of Cell Biology, Neurobiology, and Anatomy, University of Cincinnati School of Medicine, Cincinnati, Ohio 45267-0521, USA.
Bloom
G S
GS
Brady
S T
ST
D011125:Adenomatous Polyposis Coli / Q000378:metabolism; D025601:Adenomatous Polyposis Coli Protein; D000595:Amino Acid Sequence; D000818:Animals; D001370:Axonal Transport / Q000502:physiology*; D001369:Axons / Q000737:chemistry / Q000201:enzymology; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000502:physiology*; D003598:Cytoskeletal Proteins / Q000494:pharmacology*; D049832:Decapodiformes; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D020558:GTP Phosphohydrolases / Q000378:metabolism; D006657:Histones / Q000494:pharmacology; D007701:Kinetin; D008870:Microtubules / Q000737:chemistry / Q000502:physiology; D008969:Molecular Sequence Data; D009419:Nerve Tissue Proteins / Q000494:pharmacology; D025542:Neurofibromin 1; D015388:Organelles / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D011687:Purines / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology
D025601:Adenomatous Polyposis Coli Protein; D003598:Cytoskeletal Proteins; D004791:Enzyme Inhibitors; D006657:Histones; D009419:Nerve Tissue Proteins; D025542:Neurofibromin 1; D010446:Peptide Fragments; D011506:Proteins; D011687:Purines; D011994:Recombinant Proteins; C090046:olomoucine; D018844:Cyclin-Dependent Kinases; D020558:GTP Phosphohydrolases; D007701:Kinetin